LivsMed completes Korean IPO to accelerate remote robotic surgery

LivsMed has actually partnered with Sovato on telesurgery. Resource: LivsMed

LivsMed LLC recently claimed it has actually finished a going public, or IPO, on Korea’s KOSDAQ market. It increased regarding 135.9 billion ($ 94 million united state) at 55,000 per share, bringing its market capitalization to 1.4 trillion, or around $1 billion, making it a clinical modern technology “unicorn.”

The firm claimed it will certainly utilize the earnings to develop an incorporated manufacturing base, fund r & d, and reinforce relevant administration systems to sustain worldwide development throughout its item profile.

” As we scale worldwide, we continue to be concentrated on making innovative medical capacity much more easily accessible,” claimed Jung Joo Lee, Ph.D., creator and chief executive officer of LivsMed. “An advancement can not be called a development unless it can get to the masses.”

LivsMed creates systems for minimally intrusive treatments, and works together with medical professionals worldwide to enhance individual end results and broaden accessibility to innovative medical abilities. The firm is headquartered in Seoul and has a united state subsidiary in San Diego.

Roadmap consists of robotics for the united state, laparoscopic tools

In July 2025, LivsMed showed the abilities of its STARK medical robotic in a very early expediency wet-lab research study performed with telesurgery system company Sovato. In the demonstration, the doctor console lay in Santa Barbara, Calif., while the robot system remained in Chicago, sustaining long-distance connection.

The raw robot-assisted medical system is not yet accepted for usage and is except sale in the united state

LivsMed additionally intends to broaden its profile of items for minimally intrusive surgical treatment. Introduced in 2018, ArtiSential is a line of completely expressing portable laparoscopic tools made to supply wrist-like mastery.

The firm has actually broadened its system with ArtiSeal, a 90-degree expressing vessel sealant that it claimed makes it possible for multi-angle accessibility in restricted composition.

LivsMed attracts worldwide financial investment

LivsMed claimed its IPO attracted substantial rate of interest from significant residential pension plan funds and establishments, in addition to big worldwide banks headquartered in New york city and Boston. Throughout institutional publication structure, the firm reported need of about 231-to-1, with abroad involvement standing for 8.2% of the institutional need, consisting of capitalists from the united state, the Center East, and Asia.

On its market launching, LivsMed shares opened up greater than 10% over the offering cost, which it claimed shown favorable first market function. Samsung Stocks and Mirae Property Stocks acted as joint lead experts.

The buck matchings offered over made use of a currency exchange rate of 1,445 per $1 since Dec. 24, 2025.

The blog post LivsMed finishes Oriental IPO to speed up remote robot surgical treatment showed up initially on The Robotic Record.